Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase 2 12Phase NA 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gliosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × motexafin gadolinium × Clear all
NCT00089284 2019-08-14

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Northwestern University

Phase 1/2 Terminated
30 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00305864 2018-03-05

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
118 enrolled 10 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00290004 2008-09-11

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Pharmacyclics LLC.

Phase 1/2 Completed
35 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡